Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
We also measured macrophage infiltration and CLS presence
2024-04-11

We also measured macrophage infiltration and CLS presence in peri-gonadal AT from db/db mice and controls. CLS are morphological features within AT that are accurate indicators of adipocyte death and macrophage infiltration [56]. An earlier study showed that CLS macrophages account for >90% of the t
-
br Conclusion br Acknowledgments and disclosure We thank Ms
2024-04-11

Conclusion Acknowledgments and disclosure We thank Ms. Crystal Wylie for her help in the preparation of the manuscript. The development of the database upon which analyses of this study were dependent was supported by PO1 DC 00161 from the National Institute on Deafness and Other Communication
-
Golgicide A About three weeks later the
2024-04-11

About three weeks later, the patient visited our outpatient clinic complaining of gingival bleeding and pus discharge. In clinical examination bone exposure was observed in both mandibular posterior regions and bone necrosis had developed surrounding the #35=37 and 46, 47 implants installed 6 years
-
In the largest postmortem study of
2024-04-11

In the largest postmortem study of 3618 autopsied individuals, almost 75% of the individuals without Aβ pathology already harbored cortical NFT pathology mostly confined to the medial temporal regions (Murray et al., 2015). In Braak's study of 2366 autopsied individuals (Braak and Del Tredici, 2014)
-
There are several strengths and
2024-04-11

There are several strengths and weaknesses of the current investigation which merit consideration. Obviously, the current findings are important and less prone to bias than findings from traditional observational epidemiological studies, because causal investigations with the use of genetic variants
-
For patients who have taken
2024-04-11

For patients who have taken advantage of the anti-TKIs and whose follow-up has been succeeded, some partial response has been noticed with 45% (9/20) for gefitinib, 39% (9/23) for erlotinib and 56.5% (13/23) for crizotinib. A disease progression has also been observed with 35% (7/20) for gefitinib,
-
The present study showed for the first
2024-04-10

The present study showed, for the first time, that hirsutine, hirsuteine, rhynchophylline, isorhynchophylline, corynoxeine, and isocorynoxeine in yokukansan can inhibit the 5-HT3 receptor current. These data indicate that part of the effect of yokukansan against the behavioral and psychological symp
-
In addition to the above mentioned synaptic mechanisms the
2024-04-10

In addition to the above-mentioned synaptic mechanisms, the serotonergic system also has a critical role in the antidepressant effects of mGlu2/3 receptor antagonists. Indeed, we previously reported that mGlu2/3 receptor antagonists increased the firing rate of serotonin neurons in the dorsal raphe
-
543 br ACK inhibitors Since ACK activation is correlated wit
2024-04-10

ACK1 inhibitors Since ACK1 activation is correlated with poor prognosis in various cancers, strong efforts are being directed by multiple groups towards developing highly potent and specific small molecule inhibitors targeting the ACK1 kinase. At least eight small molecule kinase inhibitors have
-
During the year study period
2024-04-10

During the 4-year study period, 19.9% of men in the dutasteride group developed prostate cancer as compared to 25.1% in the placebo group, which represents an absolute risk baf312 of 5.1% for men taking dutasteride (Pe weighed against the prospect of undesirable sexual side effects and decreased qu
-
To identify the kinase s mediating
2024-04-10

To identify the kinase(s) mediating H3.3S31 phosphorylation, we devised a 96-well-plate-compatible immunostaining assay, with Dehydroepiandrosterone specific for H3.3S31ph, and utilized it to screen both a Qiagen siRNA library covering 720 human kinases and a kinase inhibitor library (Selleck) conta
-
The skin permeability barrier is important for the
2024-04-10

The skin permeability barrier is important for the prevention of loss of water and electrolytes from inside the body and for protection against the invasion of external pathogens, allergens, and harmful compounds. Multi-layered lipids, called lipid lamellae, are present in the outermost cell layer o
-
Introduction Apoptosis signal regulating kinase ASK
2024-04-10

Introduction Apoptosis signal-regulating kinase 1 (ASK1), a family member of the mitogen-activated protein (MAP) kinase kinase kinase (MAP3K) family, selectively activates the JNK and p38 MAP kinase pathways in response to various types of stresses, including oxidative stress, and subsequently indu
-
In our approach using BRET and FRET there is
2024-04-10

In our approach using BRET and FRET, there is a substantial increase in BRET and FRET signals between Giα2 or Giα3-YFP and CFP- Gγ2/Rluc-Gγ2 upon apelin-13 activation, indicating that Gαi2, Gαi3 and N-terminus of Gβ1γ2 subunits become closer without subunit dissociation. In contrast, both the FRET a
-
A phase I trial has recently evaluated enzalutamide
2024-04-10

A phase I trial has recently evaluated enzalutamide, an anti-androgen agent, in patients with ER- and AR-positive advanced BC to estimate safety and tolerability of enzalutamide therapy alone or in association to anastrozole, exemestane or fulvestrant [65]. The results of major clinical trials with
15846 records 177/1057 page Previous Next First page 上5页 176177178179180 下5页 Last page